Homogeneous BTK occupancy assay

0
IMAGE

Credit: Helen Yu, Gilead Sciences, Inc.

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. (Foster City, CA, USA) present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase (BTK) occupancy assay that can measure target engagement in peripheral blood mononuclear cells (PBMCs) and in lymph-node and bone-marrow samples. The assay provides accurate, quantitative assessment of BTK occupancy and currently is in use in ongoing tirabrutinib clinical studies.

The homogenous BTK occupancy assay's multiplexed format allows simultaneous measurement of tirabrutinib bound and total BTK levels, reducing clinical sample requirements and avoiding sampling variability observed with traditional single analyte assays.

Yu et al. take advantage of the dual wavelength emission of terbium conjugated anti-BTK antibody to serve as the energy donor for two fluorescent energy acceptors with distinct excitation and emission spectra: G2-streptavidin-bound biotinylated tirabrutinib (detects free BTK) and D2-coupled second anti-BTK antibody that binds to a different BTK epitope (detects total BTK). Additionally, the use of a common fluorescence donor serves to normalize the detection of total and free BTK with respect to each other. The assay is characterized and quantified using full-length purified recombinant human BTK protein and PBMCs derived from healthy volunteers and patients with CLL. The authors demonstrate the assay's utility using cells derived from samples from patients with CLL and DLBCL.

BTK is expressed in B cells and myeloid cells and plays an essential role in the B-cell receptor (BCR) signaling pathway. Tirabrutinib (GS-4059/ONO-4059) is a second-generation, potent, selective, irreversible BTK inhibitor. It is currently in clinical development as a treatment for chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and other lymphoid malignancies.

Integrated drug discovery and clinical development programs increasingly emphasize target engagement as a translational approach to inform pharmacodynamic and efficacy assessments. Correlation of tirabrutinib target engagement at the molecular level with pharmacological and phenotypic disease observations is crucial for establishing the appropriate clinical doses.

###

"Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement" can be accessed for free at http://journals.sagepub.com/doi/full/10.1177/2472555218786165. For more information about SLAS and its journals, visit http://www.slas.org/journals.

A PDF of this article is available to credentialed media outlets upon request. Contact [email protected]

About our Society and Journals

SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).

SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).

Follow SLAS on Twitter at @SLAS_Org.

Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.

Follow SLAS on YouTube at SLASvideo.

Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).

Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).

Media Contact

Nan Hallock
[email protected]
630-256-7527 x106
@SLAS_Org

https://www.slas.org/

Related Journal Article

http://dx.doi.org/10.1177/2472555218786165

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.